Statements (12)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:PF-06882961
|
| gptkbp:canBe |
treatment of type 2 diabetes
|
| gptkbp:CASNumber |
gptkb:1805230-56-4
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:drugClass |
GLP-1 receptor agonist
|
| gptkbp:hasMolecularFormula |
gptkb:C19H22F2N6O3S
|
| https://www.w3.org/2000/01/rdf-schema#label |
1805230-56-4
|
| gptkbp:IUPACName |
gptkb:N-[(1S)-1-(3,5-difluorophenyl)ethyl]-6-[4-(methylsulfonyl)piperazin-1-yl]pyridazine-3-carboxamide
|
| gptkbp:molecularWeight |
448.48 g/mol
|
| gptkbp:bfsParent |
gptkb:Axicabtagene_ciloleucel
|
| gptkbp:bfsLayer |
7
|